XML 124 R25.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Segment Information (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2022
Segment Reporting [Abstract] |
Schedule of Operations by Reportable Segment | Approximate information concerning the Company’s operations by reportable segment for the six and three months ended June 30, 2022 and 2021 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment
Three Months Ended June 30, 2022 |  | Product Packaging |  |  | Commercial Lending |  |  | Direct Marketing |  |  | Biotechnology |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 3,599,000 |  |  | $ | 831,000 |  |  | $ | 6,111,000 |  |  | $ | 94,000 |  |  | $ | 823,000 |  |  | $ | 313,000 |  |  | $ | 11,771,000 |
Depreciation and amortization |  |  | 177,000 |  |  |  | - |  |  |  | 159,000 |  |  |  | 278,000 |  |  |  | 2,530,000 |  |  |  | 14,000 |  |  |  | 3,158,000 |
Interest expense |  |  | 34,000 |  |  |  | - |  |  |  | (321,000 | ) |  |  | - |  |  |  | 408,000 |  |  |  | - |  |  |  | 121,000 |
Interest income |  |  | 1,000 |  |  |  | - |  |  |  | 2,000 |  |  |  | 91,000 |  |  |  | 34,000 |  |  |  | 11,000 |  |  |  | 139,000 |
Amortized debt discount |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Stock based compensation |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Net income (loss) from continuing operations |  |  | 365,000 |  |  |  | 25,000 |  |  |  | 892,000 |  |  |  | (673,000 | ) |  |  | (3,332,000 | ) |  |  | (2,687,000 | ) |  |  | (5,410,000 | )
Capital expenditures |  |  | 254,000 |  |  |  | - |  |  |  | 12,000 |  |  |  | - |  |  |  | 2,000 |  |  |  | 1,000 |  |  |  | 269,000 |
Identifiable assets |  |  | 26,688,000 |  |  |  | 52,416,000 |  |  |  | 52,267,000 |  |  |  | 56,524,000 |  |  |  | 85,436,000 |  |  |  | 9,617,000 |  |  |  | 282,948,000 |
Three Months Ended June 30,2021 |  | Product Packaging |  |  | Commercial Lending |  |  | Direct Marketing |  |  | Biotechnology |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 3,376,000 |  |  | $ | - |  |  | $ | 809,000 |  |  | $ | - |  |  | $ | - |  |  | $ | - |  |  | $ | 4,185,000 |
Depreciation and amortization |  |  | 191,000 |  |  |  | - |  |  |  | 274,000 |  |  |  | 278,000 |  |  |  | - |  |  |  | 74,000 |  |  |  | 817,000 |
Interest expense |  |  | 19,000 |  |  |  | - |  |  |  | 2,000 |  |  |  | 1,000 |  |  |  | 67,000 |  |  |  | 17,000 |  |  |  | 106,000 |
Stock based compensation |  |  | 1,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (31,000 | ) |  |  | (30,000 | )
Impairment of goodwill |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |  |  |  | - |  |  |  | - |
Net income (loss) from continuing operations |  |  | 65,000 |  |  |  | - |  |  |  | (5,985,000 | ) |  |  | (610,000 | ) |  |  | (173,000 | ) |  |  | (4,022,000 | ) |  |  | (10,725,000 | )
Capital expenditures |  |  | 1,202,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 6,565,000 |  |  |  | (57,000 | ) |  |  | 7,710,000 |
Identifiable assets |  |  | 29,463,000 |  |  |  | - |  |  |  | 44,772,000 |  |  |  | 53,717,000 |  |  |  | 10,939,000 |  |  |  | 52,270,000 |  |  |  | 191,161,000 |
Six Months Ended June 30, 2022 |  | Product Packaging |  |  | Commercial Lending |  |  | Direct Marketing |  |  | Biotechnology |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 7,168,000 |  |  | $ | 960,000 |  |  | $ | 13,043,000 |  |  | $ | 94,000 |  |  | $ | 2,497,000 |  |  | $ | 302,000 |  |  | $ | 24,064,000 |
Depreciation and amortization |  |  | 357,000 |  |  |  | - |  |  |  | 208,000 |  |  |  | 556,000 |  |  |  | 5,216,000 |  |  |  | 88,000 |  |  |  | 6,425,000 |
Interest expense |  |  | 58,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 1,441,000 |  |  |  | - |  |  |  | 1,499,000 |
Stock based compensation |  |  | 1,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 3,000 |  |  |  | 4,000 |
Income tax benefit |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Net income (loss) from continuing operations |  |  | 323,000 |  |  |  | 207,000 |  |  |  | (3,472,000 | ) |  |  | (1,289,000 | ) |  |  | (5,838,000 | ) |  |  | (4,292,000 | ) |  |  | (14,361,000 | )
Capital expenditures |  |  | 943,000 |  |  |  | - |  |  |  | 14,000 |  |  |  | - |  |  |  | 15,000 |  |  |  | 4,000 |  |  |  | 976,000 |
Identifiable assets |  |  | 26,688,000 |  |  |  | 52,416,000 |  |  |  | 52,267,000 |  |  |  | 56,524,000 |  |  |  | 85,436,000 |  |  |  | 9,617,000 |  |  |  | 282,948,000 |
Six Months Ended June 30,2021 |  | Product Packaging |  |  | Commercial Lending |  |  | Direct Marketing |  |  | Biotechnology |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 7,237,000 |  |  | $ | - |  |  | $ | 1,416,000 |  |  | $ | - |  |  | $ | - |  |  | $ | - |  |  | $ | 8,653,000 |
Depreciation and amortization |  |  | 307,000 |  |  |  | - |  |  |  | 319,000 |  |  |  | 556,000 |  |  |  | - |  |  |  | 153,000 |  |  |  | 1,335,000 |
Interest expense |  |  | 39,000 |  |  |  | - |  |  |  | 2,000 |  |  |  | 1,000 |  |  |  | 67,000 |  |  |  | 17,000 |  |  |  | 126,000 |
Stock based compensation |  |  | 1,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (16,000 | ) |  |  | (15,000 | )
Income tax benefit |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 2,691,000 |  |  |  | 2,691,000 |
Net income (loss) from continuing operations |  |  | 283,000 |  |  |  | - |  |  |  | (7,785,000 | ) |  |  | (1,308,000 | ) |  |  | (231,000 | ) |  |  | (5,746,000 | ) |  |  | (14,787,000 | )
Capital expenditures |  |  | 1,202,000 |  |  |  | - |  |  |  | 6,000 |  |  |  | - |  |  |  | 6,565,000 |  |  |  | 55,000 |  |  |  | 7,828,000 |
Identifiable assets |  |  | 29,463,000 |  |  |  | - |  |  |  | 44,772,000 |  |  |  | 53,717,000 |  |  |  | 10,939,000 |  |  |  | 52,270,000 |  |  |  | 191,161,000 |
Schedule of Disaggregation of Revenue | The following tables disaggregate our business segment revenues by major source: Schedule of Disaggregation of Revenue Printed Products Revenue Information:
Six months ended June 30, 2022 |  |  |
Packaging Printing and Fabrication |  | $ | 7,468,000 |
Commercial and Security Printing |  |  | 149,000 |
Total Printed Products |  | $ | 7,617,000 |
Six months ended June 30, 2021 |  |  |
Packaging Printing and Fabrication |  | $ | 7,056,000 |
Commercial and Security Printing |  |  | 181,000 |
Total Printed Products |  | $ | 7,237,000 |
Direct Marketing
Six months ended June 30, 2022 |  |  |
Direct Marketing Internet Sales |  | $ | 13,002,000 |
Total Direct Marketing |  | $ | 13,002,000 |
Six months ended June 30, 2021 |  |  |
Direct Marketing Internet Sales |  | $ | 1,416,000 |
Total Direct Marketing |  | $ | 1,416,000 |
Rental Income
Six months ended June 30, 2022 |  |  |
Rental income |  | $ | 3,171,000 |
Total Rental Income |  | $ | 3,171,000 |
Six months ended June 30, 2021 |  |  |  |
Rental income |  | $ | - |
Total Rental Income |  | $ | - |
Net Investment Income
Three months ended March 31, 2022 |  |  |
Net investment income |  | $ | 274,000 |
Total Management fee income |  | $ | 274,000 |
Three months ended March 31, 2021 |  |  |  |
Management fee income |  | $ | - |
Total Management fee income |  | $ | - |

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration